GeneNews last week launched of a suite of pharmacogenomic and companion diagnostic services, called SentinelGx, which are intended to be used in drug development and personalized health management applications.
In connection with the SentinelGx launch, the Toronto-based company appointed Karl Wassmann to the newly created position of executive vice president of US corporate development.
The company said its SentinelGx services include whole-blood transcriptome analysis of inflammatory pathways, immune system response, and cell signaling. The test panels used for the service will run on GeneNews' Sentinel Principle technology, and will analyze a catalog of more than 2,200 TaqMan blood RNA profiles associated with diseases, drug response, and molecular pathways.
The disease-specific panels include gene signatures for numerous types of cancer as well as autoimmune, cardiovascular, infectious, and neurological diseases.
GeneNews said that through SentinelGx, customers can access a number of laboratory services, such as RNA isolation, RNA quality control, bio-banking, real-time qPCR gene expression validation with TaqMan and SYBR Green chemistries, and as well as a range of Affymetrix gene expression profiling services.
SentinelGx also includes pharmacogenomic services, such as biomarker discovery, gauging pharmacodynamics markers for optimal dosage, stratifying patients based on drug response, disease prognosis for enrichment of trials and surrogate markers, prediction of adverse effects, and integration of DNA and RNA profiling for targeted therapies. Additionally, companion diagnostics services include biomarker development, assay design and analytical validation, clinical validation, and data analysis.